Piers Blombery
0000-0002-9902-0022
15 papers found
Refreshing results…
Persistence of UBTF tandem duplications in remission in acute myeloid leukaemia
Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia
Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all‐trans retinoic acid and arsenic trioxide sensitivity
Biallelic deleterious germline SH2B3 variants cause a novel syndrome of myeloproliferation and multi‐organ autoimmunity
Methyl‐CpG binding domain 4, DNA glycosylase (MBD4)‐associated neoplasia syndrome associated with a homozygous missense variant in MBD4: Expansion of an emerging phenotype
Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target
Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B‐acute lymphoblastic leukaemia
A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability
Recovery of natural killer cell cytotoxicity in a A91V perforinhomozygous patient following severe haemophagocytic lymphohistiocytosis
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
Diagnostic evaluation and considerations in hypocellular bone marrow failure—A focus on genomics
Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
Missing publications? Search for publications with a matching author name.